Here is Why JPMorgan is Overweight on Apellis Pharma (APLS)

Group 1 - Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is identified as one of the 10 most shorted biotech stocks to buy according to hedge funds [1] - JPMorgan increased the price target on Apellis from $36 to $37, maintaining an Overweight rating with an adjusted upside potential of over 84% [1] - A recent survey of 23 nephrologists indicated that Apellis' medication for Paroxysmal Nocturnal Hemoglobinuria, Empaveli, is positioned for significant market share gains [1] Group 2 - Wedbush noted that Apellis' fourth-quarter report aligned with consensus expectations, with key results preannounced in January [3] - Management expects Syfovre pricing to remain flat through fiscal year 2026, indicating limited growth potential [3] - Apellis is focused on developing treatments for rare blood disorders and vision-threatening eye conditions, with innovative treatments in development, including gene editing approaches [3]